Business Services
Cancer Prevention
Medical

Celcuity

$19.88
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.25 (-1.24%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell Celcuity and other stocks, options, ETFs, and crypto commission-free!

About

Celcuity Inc. Common Stock, also called Celcuity, is cellular analysis company. Read More The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. Its proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded in January 2012 by Brian Sullivan and Lance Laing and is headquartered in Minneapolis, MN.

Employees
26
Headquarters
Minneapolis, Minnesota
Founded
2012
Market Cap
205.05M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
16.59K
High Today
$20.20
Low Today
$19.01
Open Price
$20.14
Volume
7.76K
52 Week High
$31.00
52 Week Low
$13.50

Collections

Business Services
Cancer Prevention
Medical
Technology
Therapy
Health
2017 IPO
US

News

Yahoo FinanceMar 7

Krystal (KRYS) in Focus: Stock Moves 5.1% Higher

Krystal Biotech, Inc. KRYS was a big mover last session, as the company saw its shares rise more than 5% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $22.00 to $23.30 in the past one-month time frame. The move came after the company announced the opening of a cGMP facility for the clinical and commercial production of its lead product KB10...

64
MarketBeatMar 6

Stock Price, News, & Analysis for Celcuity

Celcuity Inc., a cellular analysis company, discovers cancer sub-types and commercializes diagnostic tests to enhance the response rates of cancer patients treated with targeted therapies in the United States. The company is developing CELx tests to diagnose two new sub-types of HER2-negative breast cancer. It is also developing CELx tests to diagnose 14 new potential cancer sub-types in breast, lung, colon, ovarian, kidney, bladder, and hematological cancers. The company was founded in 2012 and is headquar...

3
The Motley FoolFeb 26

Celcuity Inc. (CELC) Q4 2018 Earnings Conference Call Transcript

Celcuity Inc. (NASDAQ: CELC) Q4 2018 Earnings Conference Call , 4:30 p.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Please stand-by. Your program is about to begin. (Operator Instructions) Now I would like to turn the call over to Brian Sullivan, Chief Executive Officer. Brian Sullivan -- Chief Executive Officer and Co-Founder Thank you and good afternoon, everyone. We announced the financial results for our fourth quarter and year ended Dece...

12

Earnings

-$0.20
-$0.18
-$0.16
-$0.14
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 13, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.